Yahoo Finance

New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease

The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regions Phase 1b Study of BIIB080 showed dose-dependent and sustained reduction of tau ...
Nasdaq

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an ...
Morningstar

Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease

Biogen has won a U.S. Food and Drug Administration fast-track designation for its investigational BIIB080 therapy for the treatment of Alzheimer's disease. Biogen on Wednesday said BIIB080 is the ...
Healio

Biogen’s investigational therapy reduced tau protein levels in patients with Alzheimer’s

Please provide your email address to receive an email when new articles are posted on . Phase 1b trial of BII080 demonstrated dose-dependent and sustained reduction of tau protein in CSF, as well as ...
STAT

Biogen’s tau-lowering drug slows cognitive decline in early study of Alzheimer’s disease

An experimental treatment for Alzheimer’s disease that removes a toxic protein called tau from brain cells showed “favorable trends” across several measures of cognition and function in a small study ...
Business Insider

New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease

CARLSBAD, Calif., March 29, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported that its partner Biogen presented new Phase 1b clinical data showing that IONIS-MAPT Rx ...